Gamehost Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 1.7K
- Market Cap
- -
- Introduction
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.
Shield Post-Approval Study Protocol
- Conditions
- Colo-rectal Cancer
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 3375
- Registration Number
- NCT06880055
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
- Conditions
- Non-small Cell Lung CancerColorectal CancerBreast Cancer
- Interventions
- Diagnostic Test: Guardant360
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT05935384
- Locations
- 🇺🇸
Orchard Healthcare Research Inc., Skokie, Illinois, United States
Screening for High Frequency Malignant Disease
- Conditions
- Lung Cancer
- Interventions
- Device: Low-dose CT scan
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 12000
- Registration Number
- NCT05117840
- Locations
- 🇺🇸
El Paso Pulmonary Associates, El Paso, Texas, United States
🇺🇸Allure Heath at Mt. Olympus Medical Research, Friendswood, Texas, United States
🇺🇸Best Cancer Care & Hematology - Biopharma Informatic, Houston, Texas, United States
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Conditions
- Bladder CarcinomaUreter CarcinomaRenal Pelvis CarcinomaNon-small Cell Lung CancerInvasive Breast CarcinomaCutaneous MelanomaEsophageal CarcinomaGastroesophageal Junction CarcinomaGastric AdenocarcinomaPancreatic Adenocarcinoma
- Interventions
- Diagnostic Test: Guardant Reveal
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 1050
- Registration Number
- NCT05059444
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸The Oncology Institute of Hope & Innovation, Lakeland, Florida, United States
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- Diagnostic Test: Guardant360 test
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT04436393
- Locations
- 🇺🇸
Guardant Health, Redwood City, California, United States
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
- Conditions
- Colorectal Cancer
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 44467
- Registration Number
- NCT04136002
- Locations
- 🇺🇸
Cary Gastro Associates, Cary, North Carolina, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Pinnacle Research Group, LLC, Anniston, Alabama, United States
Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records
- Conditions
- Non-Hematologic Malignancy
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03625557
- Locations
- 🇺🇸
Guardant Health, Redwood City, California, United States
Noninvasive vs. Invasive Lung Evaluation
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Diagnostic Test: Guardant360
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 306
- Registration Number
- NCT03615443
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
- Conditions
- Non-small Cell Lung Cancer Metastatic
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Guardant Health, Inc.
- Target Recruit Count
- 311
- Registration Number
- NCT03477474
- Locations
- 🇺🇸
Holy Cross, Fort Lauderdale, Florida, United States